[go: up one dir, main page]

TNSN07233A1 - Macrolides - Google Patents

Macrolides

Info

Publication number
TNSN07233A1
TNSN07233A1 TNP2007000233A TNSN07233A TNSN07233A1 TN SN07233 A1 TNSN07233 A1 TN SN07233A1 TN P2007000233 A TNP2007000233 A TN P2007000233A TN SN07233 A TNSN07233 A TN SN07233A TN SN07233 A1 TNSN07233 A1 TN SN07233A1
Authority
TN
Tunisia
Prior art keywords
des
composés
pour
les
est
Prior art date
Application number
TNP2007000233A
Other languages
English (en)
Inventor
Louis Stanley Chupak
Mark Edward Flanagan
Takushi Kaneko
Thomas Victor Magee
Mark Carl Noe
Usa Reilly
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35809765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN07233(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN07233A1 publication Critical patent/TNSN07233A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Tires In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des composés macrolides proprement dits, représentés ci-dessous et définis dans le présent mémoire, et leur utilisation, par exemple comme agents antibactériens et antiprotozoaires chez des animaux, y compris les êtres humains : formule (I). Il est révélé également des procédés pour la préparation des composés, des intermédiaires, des compostions pharmaceutique contenant ces composés, et des méthodes pour le traitement et la prévention d'une maladie en administrant les composés à des sujets en ayant besoin. Cet abrégé est seulement un extrait et ne limite pas la présente invention.
TNP2007000233A 2004-12-21 2007-06-20 Macrolides TNSN07233A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63809704P 2004-12-21 2004-12-21
US71753005P 2005-09-14 2005-09-14
PCT/IB2005/003829 WO2006067589A1 (fr) 2004-12-21 2005-12-12 Macrolides

Publications (1)

Publication Number Publication Date
TNSN07233A1 true TNSN07233A1 (fr) 2008-11-21

Family

ID=35809765

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000233A TNSN07233A1 (fr) 2004-12-21 2007-06-20 Macrolides

Country Status (35)

Country Link
US (1) US7462600B2 (fr)
EP (2) EP2233493A1 (fr)
JP (1) JP4111994B1 (fr)
KR (1) KR100897678B1 (fr)
CN (1) CN101120011A (fr)
AP (1) AP2007004026A0 (fr)
AR (1) AR052824A1 (fr)
AT (1) ATE459633T1 (fr)
AU (1) AU2005317735B2 (fr)
BR (1) BRPI0519135A2 (fr)
CA (1) CA2591746A1 (fr)
CR (1) CR9202A (fr)
DE (1) DE602005019786D1 (fr)
DK (1) DK1836211T3 (fr)
EA (1) EA011281B1 (fr)
ES (1) ES2339871T3 (fr)
GE (1) GEP20094834B (fr)
GT (1) GT200500378A (fr)
HN (1) HN2005036113A (fr)
HR (1) HRP20100253T1 (fr)
IL (1) IL183661A0 (fr)
MA (1) MA29108B1 (fr)
MX (1) MX2007007598A (fr)
NL (1) NL1030713C2 (fr)
NO (1) NO20073367L (fr)
PE (1) PE20060948A1 (fr)
PL (1) PL1836211T3 (fr)
PT (1) PT1836211E (fr)
SI (1) SI1836211T1 (fr)
TN (1) TNSN07233A1 (fr)
TW (1) TW200626608A (fr)
UA (1) UA85937C2 (fr)
UY (1) UY29285A1 (fr)
WO (1) WO2006067589A1 (fr)
ZA (1) ZA200705108B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367669B2 (en) * 2005-06-15 2013-02-05 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
US9133212B1 (en) 2005-06-15 2015-09-15 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
EP1928893A2 (fr) 2005-08-24 2008-06-11 Rib-X Pharmaceuticals, Inc. Composes de triazole et preparation et utilisation de ces composes
WO2008110918A2 (fr) * 2007-03-13 2008-09-18 Pfizer Products Inc. Macrolides
AU2008227216A1 (en) * 2007-03-21 2008-09-25 Creative Antibiotics Sweden Ab Method and means for preventing and inhibiting type III secretion in infections caused by gram-negative bacteria
WO2009053259A1 (fr) * 2007-10-25 2009-04-30 Sandoz Ag Procédé de fabrication de télithromycine
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
RU2495878C2 (ru) 2007-12-21 2013-10-20 Ф.Хоффманн-Ля Рош Аг Гетероциклические антивирусные соединения
JP5662445B2 (ja) 2009-08-13 2015-01-28 バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ 新規マクロライド及びその使用
HRP20160168T1 (hr) * 2010-03-22 2016-03-25 Cempra Pharmaceuticals Inc Kristalne forme makrolida i njihova uporaba
EP2696873B1 (fr) 2011-04-12 2022-08-03 The United States of America, as represented by The Secretary, Department of Health and Human Services Inhibiteurs du canal anionique de surface de plasmodium pour le traitement ou la prévention de la malaria
CN102558047B (zh) * 2011-12-14 2013-10-30 天津药物研究院药业有限责任公司 3-甲基喹啉的制备方法
WO2013148891A1 (fr) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Formulations parentérales pour l'administration d'antibiotiques macrolides
US9611224B2 (en) 2012-07-13 2017-04-04 Hoffmann-La Roche Inc. Antiproliferative benzo [B] azepin-2-ones
KR101663864B1 (ko) * 2013-04-19 2016-10-07 영남대학교 산학협력단 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 약학조성물
TW201534586A (zh) 2013-06-11 2015-09-16 Orion Corp 新穎ｃｙｐ１７抑制劑／抗雄激素劑
CN103739643A (zh) * 2013-12-30 2014-04-23 华东理工大学 利用分子印迹技术对红霉素进行回收分离纯化的方法
CN104230891B (zh) * 2014-08-27 2016-03-30 于宗光 一种托匹司他的制备方法
CN110234323A (zh) * 2016-10-04 2019-09-13 Ti生物制药有限公司 具有抗菌活性的酮内酯
CN114340616A (zh) * 2019-06-04 2022-04-12 海格生物科学有限责任公司 作为食欲肽拮抗剂的吡唑和咪唑衍生物、组合物以及方法
JP2022534704A (ja) 2019-06-04 2022-08-03 ヘイガー バイオサイエンシズ，エルエルシー オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法
CN111793022A (zh) * 2020-04-27 2020-10-20 滁州拜奥生物科技有限公司 一种3-甲基喹啉的制备方法
EP4580620A2 (fr) * 2022-09-01 2025-07-09 Hager Biosciences, LLC Dérivés de pyrazole et d'imidazole utilisés en tant que modulateurs des récepteurs double d'orexine et d'opioïdes kappa, composition, procédés de traitement de troubles neurologiques et psychiatriques

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2653899A (en) 1952-04-14 1953-09-29 Lilly Co Eli Erythromycin, its salts, and method of preparation
US2823203A (en) 1954-06-24 1958-02-11 Abbott Lab Method of producing substantially pure erythromycin a
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4742049A (en) * 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
US5075289A (en) 1988-06-07 1991-12-24 Abbott Laboratories 9-r-azacyclic erythromycin antibiotics
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
US5523399A (en) 1991-12-27 1996-06-04 Taisho Pharmaceutical Co., Ltd. 5-O-desosaminylerythronolide derivatives
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2697524B1 (fr) * 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
FR2727969B1 (fr) * 1994-12-09 1997-01-17 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US5747466A (en) * 1995-11-08 1998-05-05 Abbott Laboratories 3-deoxy-3-descladinose derivatives of erythromycins A and B
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
AU2340797A (en) * 1996-05-07 1997-11-26 Abbott Laboratories 6-o-substituted erythromycins and method for making them
US5750510A (en) * 1997-04-04 1998-05-12 Abbott Laboratories 3-descladinose-2,3-anhydroerythromycin derivatives
FR2748746B1 (fr) * 1996-05-14 1998-08-14 Hoechst Marion Roussel Inc Nouveau procede d'isomerisation du radical methyle en 10 de derives de l'erythromycine
US6271255B1 (en) 1996-07-05 2001-08-07 Biotica Technology Limited Erythromycins and process for their preparation
FR2751656B1 (fr) * 1996-07-24 1998-10-16 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
EP1291351B1 (fr) 1996-09-04 2005-07-13 Abbott Laboratories Cétolides substitués en 6-o possédant une activité antibactérienne
US5804565A (en) 1996-09-24 1998-09-08 Taisho Pharmaceutical Co., Ltd. Erythromycin A derivatives
JP4077882B2 (ja) * 1996-11-27 2008-04-23 大正製薬株式会社 エリスロマイシンａ誘導体
AU6421398A (en) 1997-03-24 1998-10-20 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
AU6932098A (en) 1997-05-09 1998-12-08 Pfizer Products Inc. Erythromycin derivatives
US20020025937A1 (en) 2000-03-20 2002-02-28 Yong-Jin Wu 9-oxime erythromycin derivatives
EP0895999A1 (fr) 1997-08-06 1999-02-10 Pfizer Products Inc. Macrolides antibiotiques substitués C"-4
ZA987689B (en) 1997-09-02 1999-02-24 Abbott Lab 3-descladinose 6-O substituted erythromycin derivatives
US6034069A (en) * 1997-09-30 2000-03-07 Abbott Laboratories 3-'N-modified 6-O-substituted erythromycin ketolide derivatives having antibacterial activity
JP2003527301A (ja) 1997-10-29 2003-09-16 大正製薬株式会社 エリスロマイシンａ誘導体
HN1998000159A (es) * 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
PA8461401A1 (es) 1997-10-29 2000-05-24 Pfizer Prod Inc Derivados de eritromicina triciclicos
AP1060A (en) * 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
AP9801420A0 (en) 1998-01-02 1998-12-31 Pfizer Prod Inc Novel macrolides.
ES2226282T3 (es) 1998-03-03 2005-03-16 Pfizer Products Inc. Antibioticos macrilidos de 3,6-cetal.
US5955440A (en) * 1998-03-27 1999-09-21 Abbott Laboratories Macrolide LHRH antagonists
US6248719B1 (en) 1998-06-03 2001-06-19 Pfizer Inc Tricyclic 3-keto derivatives of 6-O-methylerthromycin
JP4573925B2 (ja) * 1998-07-09 2010-11-04 アベンティス・ファーマ・ソシエテ・アノニム 新規のエリスロマイシン誘導体、その製造方法及びその薬剤としての使用
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) * 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US6262030B1 (en) 1998-11-03 2001-07-17 Pfizer Inc. Erythromycin derivatives
SK5812001A3 (en) 1998-11-03 2001-12-03 Pfizer Prod Inc Novel macrolide antibiotics
AU6484199A (en) * 1998-12-10 2000-06-26 Pfizer Products Inc. Carbamate and carbazate ketolide antibiotics
OA11753A (en) 1999-01-27 2005-07-19 Pfizer Prod Inc Ketolide antibiotics.
US6054435A (en) * 1999-03-19 2000-04-25 Abbott Laboratories 6-O-substituted macrolides having antibacterial activity
US6395710B1 (en) * 1999-04-16 2002-05-28 Kosan Biosciences, Inc. Macrolide antiinfective agents
CN1373767A (zh) * 1999-04-16 2002-10-09 奥索-麦克尼尔药品公司 酮式大环内酯抗菌剂
US6939861B2 (en) 1999-04-16 2005-09-06 Kosan Biosciences, Inc. Amido macrolides
US20020077302A1 (en) 1999-04-23 2002-06-20 Yong-Jin Wu Tricyclic erythromycin derivatives
US20020061857A1 (en) 1999-04-23 2002-05-23 Yong-Jin Wu 9-amino-3-oxo erythromycin derivatives
US6355620B1 (en) * 1999-05-14 2002-03-12 Abbott Laboratories C-2 modified erythromycin derivatives
KR20020016799A (ko) 1999-05-24 2002-03-06 데이비드 존 우드 13-메틸-에리트로마이신 유도체
JP2001072669A (ja) 1999-09-07 2001-03-21 Showa Kako Kk ７−クロロ−２，４（１ｈ，３ｈ）−キナゾリンジオンの製造方法
US6569836B2 (en) * 1999-12-02 2003-05-27 Abbott Laboratories 6-O-alkyl-2-nor-2-substituted ketolide derivatives
EP1114826A3 (fr) 1999-12-29 2001-10-31 Pfizer Products Inc. Macrolides antibactériennes et prokinétiques
EP1122261A3 (fr) 2000-01-31 2001-09-26 Pfizer Products Inc. Macrolides antibactériennes à 13 ou 14 chainons
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
EP1146051A3 (fr) 2000-04-10 2001-10-31 Pfizer Products Inc. Dérivées de l' érythromycine A
US20020061856A1 (en) 2000-04-24 2002-05-23 Yong-Jin Wu Novel tricyclic erythromycin derivatives
EP1167376B1 (fr) 2000-06-30 2004-07-14 Pfizer Products Inc. Macrolides antibiotiques
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
CZ20031751A3 (cs) 2000-12-21 2004-03-17 Glaxo Group Limited Makrolidy
US20020132782A1 (en) * 2001-01-18 2002-09-19 Zhenkun Ma 9-amino erythromycin derivatives with antibacterial activity
CA2451391A1 (fr) * 2001-07-03 2003-01-16 Chiron Corporation Macrolides et cetolides d'erythromycine modifiee c12 a activite antibacterienne
US7022679B2 (en) 2002-05-13 2006-04-04 Enanta Pharmaceuticals, Inc. Processes for the preparation of 6-11 bicyclic erythromycin derivatives
US7064110B2 (en) 2002-05-13 2006-06-20 Enanta Pharmaceuticals, Inc. 6-11 bicycle ketolide derivatives
JPWO2004094407A1 (ja) 2003-04-21 2006-07-13 第一製薬株式会社 ５員複素環誘導体
WO2006080954A1 (fr) 2004-07-28 2006-08-03 Ranbaxy Laboratories Limited Derives de cetolides agents antibacteriens
WO2006046112A2 (fr) 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Derives de cetolides utiles comme agents antibacteriens
GB0424951D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
JP2008522978A (ja) 2004-12-07 2008-07-03 エナンタ ファーマシューティカルズ インコーポレイテッド ３，６−ビシクロライド
US7312201B2 (en) 2004-12-13 2007-12-25 Enanta Pharmaceuticals, Inc. Tetracyclic bicyclolides
WO2006065721A2 (fr) 2004-12-13 2006-06-22 Enanta Pharmaceuticals, Inc. Bicyclolides de 11, 12-lactone

Also Published As

Publication number Publication date
WO2006067589A1 (fr) 2006-06-29
HN2005036113A (es) 2010-12-06
JP2008524319A (ja) 2008-07-10
JP4111994B1 (ja) 2008-07-02
PE20060948A1 (es) 2006-10-11
AU2005317735B2 (en) 2009-06-04
NO20073367L (no) 2007-09-05
ZA200705108B (en) 2009-01-28
ES2339871T3 (es) 2010-05-26
EA011281B1 (ru) 2009-02-27
MX2007007598A (es) 2007-07-25
US20060135447A1 (en) 2006-06-22
AR052824A1 (es) 2007-04-04
EP1836211A1 (fr) 2007-09-26
NL1030713C2 (nl) 2006-12-12
EA200701113A1 (ru) 2007-12-28
GT200500378A (es) 2006-11-28
HRP20100253T1 (hr) 2010-06-30
PT1836211E (pt) 2010-04-08
EP1836211B1 (fr) 2010-03-03
EP2233493A1 (fr) 2010-09-29
MA29108B1 (fr) 2007-12-03
BRPI0519135A2 (pt) 2008-12-23
CN101120011A (zh) 2008-02-06
UY29285A1 (es) 2006-07-31
GEP20094834B (en) 2009-11-25
NL1030713A1 (nl) 2006-06-22
ATE459633T1 (de) 2010-03-15
IL183661A0 (en) 2007-09-20
CR9202A (es) 2007-07-16
AP2007004026A0 (en) 2007-06-30
DE602005019786D1 (de) 2010-04-15
PL1836211T3 (pl) 2010-07-30
TW200626608A (en) 2006-08-01
CA2591746A1 (fr) 2006-06-29
AU2005317735A1 (en) 2006-06-29
SI1836211T1 (sl) 2010-04-30
KR20070089191A (ko) 2007-08-30
UA85937C2 (uk) 2009-03-10
US7462600B2 (en) 2008-12-09
DK1836211T3 (da) 2010-05-17
KR100897678B1 (ko) 2009-05-14

Similar Documents

Publication Publication Date Title
TNSN07233A1 (fr) Macrolides
TNSN06358A1 (fr) Methyl-aryl-ou-heteroaryl-amides substitues
TNSN06051A1 (fr) Derives de piperazine pour le traitement d'infections par le hiv
MA33731B1 (fr) Inhibiteurs du virus de l'hépatite c
MA57933B1 (fr) Composés hautement actifs contre la covid-19
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
BR0207657A (pt) Uma ou mais sequências de polinucleotìdeos isoladas, vetor, célula hospedeira, composição, disposição, métodos para diagnosticar as osteoartrites branda, moderada, acentuada e grave em um paciente, para identificar um agente que aumenta ou diminui a expressão de uma sequência de polinucleotìdeos, para preparar uma coleção de cdna de condrócito, e para fabricar uma disposição, e conjunto
TNSN07375A1 (fr) Acides nucleiques de liaison a la ghreline
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
TNSN06200A1 (fr) Derives de quinoleine nouveaux
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
TNSN07066A1 (fr) Inhibiteurs de l'arn-polymerase, dependant d'arn, du virus de l'hepatite c, et compositions et traitements les utilisant
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
BR0305426A (pt) Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA31319B1 (fr) Dérivés de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA27009A1 (fr) Derives de pyrazole pour le traitement d'une infection par le vih
MA33209B1 (fr) Inhibiteurs de la replication du virus de l'hepatite c
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
WO2001081310A8 (fr) 1-aroyle-piperidinyle benzamidines
MA34308B1 (fr) Triazolopyridines substituées
MA31586B1 (fr) Dérivés d'alcools alkyliques de 1-phényl-2-pyridinyle en tant qu'inhibiteurs de la phosphodiestérase
MA34559B1 (fr) Formulation pour le traitement du cancer
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA24729A1 (fr) Macrolides nouveaux.